Skip to main content

Table 2 Use of medication against allergy during the most recent grass pollen season (n (%))

From: Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation

  Completed (n = 107) On treatment (n = 55) Discontinued (n = 45) p-value
No medication 9 (8%) 3 (5%) 3 (7%) 0.78
Oral antihistamines 86 (80%) 50 (91%) 39 (87%) 0.19
Montelukast 9 (8% 14 (25%) 9 (20%) 0.01
Oral corticosteroids 6 (6%) 3 (5%) 3 (7%) 0.96
Nasal antihistamines 11 (10%) 13 (24%) 6 (13%) 0.07
Nasal corticosteroids 49 (46%) 33 (60%) 24 (53%) 0.22
Nasal cromoglycate 5 (5%) 1 (2%) 5 (11%) 0.11
Antihistamine eyedrops 31 (29%) 22 (40%) 17 (38%) 0.30
Cromone eyedrops 25 (23%) 16 (29%) 12 (27%) 0.72
Inhaled corticosteroids 35 (33%) 27 (49%) 15 (33%) 0.10
Short acting beta-2 agonists 16 (15%) 19 (35%) 11 (24%S) 0.02
Long acting beta-2 agonists 2 (2) 3 (5) 3 (7) 0.29